Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Losartan (DuP-753) 是一种血管紧张素II 受体拮抗剂,能够与血管紧张素II 竞争性结合AT1受体(IC50:20 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
500 mg | ¥ 333 | 现货 | ||
1 g | ¥ 418 | 现货 | ||
5 g | ¥ 970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 418 | 现货 |
产品描述 | Losartan (DuP-753) is an angiotensin II receptor antagonist. |
靶点活性 | AT1 receptor:20 nM |
体外活性 | Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC50) is 20 nM[1]. Losartan (40?μM) affects ISC but prevents the effect of ANGII on ISC[2]. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone[3]. |
体内活性 | Losartan (0.6 g/L, p.o.) -treated Fbn1C1039 g/+ mice show a reduction in distal airspace caliber relative to placebo-treated Fbn1C1039 g/+ animals. The doses of losartan and propranolol are titrated to achieve comparable hemodynamic effects. Analysis of pSmad2 nuclear staining reveals that losartan antagonizes TGF-β signaling in the aortic wall of Fbn1C1039 g/+ mice. Losartan can improve disease manifestations in the lungs, an event that cannot plausibly relate to improved hemodynamics[4]. Losartan (10 mg/kg, intraarterial injection) increases blood angiotensin levels four- to sixfold. Losartan (10 mg/kg, i.p.) increases plasma renin levels 100-fold; plasma angiotensinogen levels decreases to 24% of control; and plasma aldosterone levels are unchanged[5]. |
细胞实验 | An MTT assay is used to measure cell proliferation and viability. For the assay, 5000 cells in 200?μL media per well are seeded in a 96 well plate. After overnight incubation to allow for cell attachment, the medium is removed by suction. MTT at 1?mg/mL concentration in serum-free medium is added and then incubated for 4?h at 37°C. After removal of MTT solution, 100?μL of DMSO is added to dissolve formazan crystals. Absorbance at 570?nm and at 600?nm as a reference is then measured using a microplate reader. The difference in absorbance is thus relative to the extent of cell survival. |
别名 | DuP-753, 氯沙坦, 洛沙坦 |
分子量 | 422.91 |
分子式 | C22H23ClN6O |
CAS No. | 114798-26-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 198.6 mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3646 mL | 11.8228 mL | 23.6457 mL | 59.1142 mL |
5 mM | 0.4729 mL | 2.3646 mL | 4.7291 mL | 11.8228 mL | |
10 mM | 0.2365 mL | 1.1823 mL | 2.3646 mL | 5.9114 mL | |
20 mM | 0.1182 mL | 0.5911 mL | 1.1823 mL | 2.9557 mL | |
50 mM | 0.0473 mL | 0.2365 mL | 0.4729 mL | 1.1823 mL | |
100 mM | 0.0236 mL | 0.1182 mL | 0.2365 mL | 0.5911 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Losartan 114798-26-4 Endocrinology/Hormones RAAS DuP 753 Angiotensin Receptor DuP753 DuP-753 氯沙坦 inhibit Inhibitor 洛沙坦 inhibitor